Vir Biotechnology Q1 net loss widens

Vir Biotechnology

06/05/2026 21:12

Overview

US biopharma firm's Q1 net loss widened yr/yr as revenue turned negative

Company ended Q1 with $809.3 mln in cash and investments, excluding Astellas payments

Global collaboration with Astellas closed, advancing prostate cancer drug development

Outlook

Company expects topline Phase 3 ECLIPSE 1 trial data in Q4 2026

Vir anticipates initiating pivotal Phase 3 trials for VIR-5500 in 2027

Company expects cash, cash equivalents and investments to fund operations into H2 2028

Result Drivers

R&D EXPENSES - Q1 R&D costs fell due to absence of prior-year $30 mln Alnylam agreement expense, partly offset by higher CHD manufacturing and clinical costs

CLINICAL PROGRAM PROGRESS - Co cited advancement of CHD and oncology trials, including positive data and new patient dosing, as key operational activities

Company press release: ID:nBw3qjhv8a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.85
Q1 Net Income
-$125.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Vir Biotechnology Inc is $19.50, about 94.8% above its May 5 closing price of $10.01

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)